Table 3. Studies using PET-directed... | American Society of Hematology

Table 3.

Studies using PET-directed approaches in limited-stage HL

Study	PET-negative rate (% considered for RT omission)	Treatment of PET-negative patients	Median follow-up, mo	3- to 5-y PFS for PET-negative patients
Study	PET-negative rate (% considered for RT omission)	Treatment of PET-negative patients	Median follow-up, mo	n	%
United Kingdom RAPID³	75%^*	ABVD × 3 cycles ABVD × 3 cycles + RT	62	211 209	90.8 94.6
EORTC/LYSA/FIL H10²⁶	81%†	ABVD × 4-6 cycles ABVD × 3-4 cycles + RT	54	540 519	88.3 93.4
ALLIANCE/CALGB 50604²⁷	91%‡	ABVD × 4 cycles	46	135	91
GHSG HD16²⁹	66%^*	ABVD × 2 cycles ABVD × 2 cycles + RT	46	300 328	86.1 93.4
Current study	95%^*	ABVD × 2-6 cycles + BV	47	37	100

Study	PET-negative rate (% considered for RT omission)	Treatment of PET-negative patients	Median follow-up, mo	3- to 5-y PFS for PET-negative patients
Study	PET-negative rate (% considered for RT omission)	Treatment of PET-negative patients	Median follow-up, mo	n	%
United Kingdom RAPID³	75%^*	ABVD × 3 cycles ABVD × 3 cycles + RT	62	211 209	90.8 94.6
EORTC/LYSA/FIL H10²⁶	81%†	ABVD × 4-6 cycles ABVD × 3-4 cycles + RT	54	540 519	88.3 93.4
ALLIANCE/CALGB 50604²⁷	91%‡	ABVD × 4 cycles	46	135	91
GHSG HD16²⁹	66%^*	ABVD × 2 cycles ABVD × 2 cycles + RT	46	300 328	86.1 93.4
Current study	95%^*	ABVD × 2-6 cycles + BV	47	37	100

CALGB, Cancer and Leukemia Group B; EORTC/LYSA/FIL, European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi; GHSG, German Hodgkin Study Group.

Deauville ≤2.

†

International Harmonization Project (IHP) criteria.

‡

Deauville ≤3.

View Large

This Feature Is Available To Subscribers Only